Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy
Public ClinicalTrials.gov record NCT02460094. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Intravenously Administered BMS-986168 in Patients With Progressive Supranuclear Palsy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety and tolerability of multiple ascending intravenous infusions of BMS-986168 and to assess the pharmacokinetics and immunogenicity of BIIB092, and pharmacodynamics of BIIB092 on cerebrospinal fluid (CSF) extracellular tau (eTau) concentrations in participants with Progressive Supranuclear Palsy.
Study identification
- NCT ID
- NCT02460094
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 48 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 41 Years to 86 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 1, 2015
- Primary completion
- Oct 18, 2016
- Completion
- Oct 18, 2016
- Last update posted
- Sep 3, 2018
2015 – 2016
United States locations
- U.S. sites
- 13
- U.S. states
- 9
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The University of Alabama at Birmingham | Birmingham | Alabama | — | — |
| David Geffen School of Medicine at UCLA | Los Angeles | California | — | — |
| University of California San Diego | San Diego | California | — | — |
| University of California, San Francisco, Medical Center at Parnassus | San Francisco | California | — | — |
| Parkinsons Disease and Movement Disorders Center of Boca Raton | Boca Raton | Florida | — | — |
| University of Florida College of Medicine | Gainesville | Florida | — | — |
| University of South Florida | Tampa | Florida | — | — |
| The University of Chicago Department of Neurology | Chicago | Illinois | — | — |
| University of Minnesota Medical School | Minneapolis | Minnesota | — | — |
| Robert Wood Johnson Medical School | New Brunswick | New Jersey | — | — |
| Columbia University Medical Center | New York | New York | — | — |
| Hospital of the University of Pennsylvania | Philadelphia | Pennsylvania | — | — |
| The University of Texas Southwestern Medical Center | Dallas | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02460094, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 3, 2018 · Synced Sep 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02460094 live on ClinicalTrials.gov.